What is the address of DRAGONPHARMA?

The registered office of DRAGONPHARMA is located at Rue Jean Jean 3, 7340 Colfontaine.

Is DRAGONPHARMA still active?

Yes. According to the CBE (30 October 2026) DRAGONPHARMA is active, legal situation “Normale toestand”, started on 5 July 2012.

Is DRAGONPHARMA registered on Peppol?

Yes, DRAGONPHARMA is registered on the Peppol network with ID 0208:0847159297.

What is the enterprise number of DRAGONPHARMA?

The enterprise number of DRAGONPHARMA is BE0847159297.

When was DRAGONPHARMA founded?

DRAGONPHARMA was founded on 5 July 2012.

Who are the directors of DRAGONPHARMA?

According to the 2025 annual accounts, the directors of DRAGONPHARMA are: Pascal Conem.

Is DRAGONPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 July 2012; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DRAGONPHARMA make in 2025?

DRAGONPHARMA recorded a loss after taxes of € 8,675 in financial year 2025.

What is the revenue of DRAGONPHARMA?

As a small company, DRAGONPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 29,249.

DRAGONPHARMA (Private Limited) - Colfontaine

Dossier DRAGONPHARMA, printed on 30 October 2026 from databakkes.be/en/0847159297/dragonpharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 41 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

DRAGONPHARMA from Colfontaine, company number BE0847159297, closed financial year 2025 with a result of € -8,675 after tax. For that financial year DRAGONPHARMA recorded a gross margin of € 29,249 and equity of € 355,790. Compared with financial year 2024, the result moved from € -13,096 to € -8,675. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.

What it is worth Healthy

€ 355,790

▼ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -8,675

▲ 34 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1,699

▼ 98% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 337,240.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 28,191

▼ 38% vs 2024

€ 17,628 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 7,854

▼ 84% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 19,644 Gross margin 2022: € 19,644 First fiscal year in the series	€ 21,876 Gross margin 2023: € 21,876 ▲ 11% vs 2022 (€ 19,644) Favourable step	€ 23,288 Gross margin 2024: € 23,288 ▲ 6% vs 2023 (€ 21,876) Favourable step	€ 29,249 Gross margin 2025: € 29,249 ▲ 26% vs 2024 (€ 23,288) Favourable step	▲ 26%
Profit after taxes	€ -2,672 Profit after taxes 2022: € -2,672 First fiscal year in the series	€ -9,050 Profit after taxes 2023: € -9,050 ▼ € 6,378 vs 2022 (€ -2,672) Unfavourable step	€ -13,096 Profit after taxes 2024: € -13,096 ▼ € 4,046 vs 2023 (€ -9,050) Unfavourable step	€ -8,675 Profit after taxes 2025: € -8,675 ▲ € 4,420 vs 2024 (€ -13,096) Favourable step	▲ € 4,420
Equity	€ 386,611 Equity 2022: € 386,611 First fiscal year in the series	€ 377,561 Equity 2023: € 377,561 ▼ 2% vs 2022 (€ 386,611) Unfavourable step	€ 364,465 Equity 2024: € 364,465 ▼ 3% vs 2023 (€ 377,561) Unfavourable step	€ 355,790 Equity 2025: € 355,790 ▼ 2% vs 2024 (€ 364,465) Unfavourable step	▼ 2%
Total debts	€ 79,849 Total debts 2022: € 79,849 First fiscal year in the series	€ 112,469 Total debts 2023: € 112,469 ▲ 41% vs 2022 (€ 79,849) Unfavourable step	€ 393,919 Total debts 2024: € 393,919 ▲ 250% vs 2023 (€ 112,469) Unfavourable step	€ 374,160 Total debts 2025: € 374,160 ▼ 5% vs 2024 (€ 393,919) Favourable step	▼ 5%
Cash	€ 12,173 Cash 2022: € 12,173 First fiscal year in the series	€ 10,063 Cash 2023: € 10,063 ▼ 17% vs 2022 (€ 12,173) Unfavourable step	€ 68,719 Cash 2024: € 68,719 ▲ € 58,656 vs 2023 (€ 10,063) Favourable step	€ 1,699 Cash 2025: € 1,699 ▼ 98% vs 2024 (€ 68,719) Unfavourable step	▼ 98%
Land & buildings	€ 213,963 Land & buildings 2022: € 213,963 First fiscal year in the series	€ 202,220 Land & buildings 2023: € 202,220 ▼ 5% vs 2022 (€ 213,963) Unchanged	€ 190,477 Land & buildings 2024: € 190,477 ▼ 6% vs 2023 (€ 202,220) Unchanged	€ 776,986 Land & buildings 2025: € 776,986 ▲ € 586,509 vs 2024 (€ 190,477) Unchanged	▲ € 586,509
Retained profit	€ 368,061 Retained profit 2022: € 368,061 First fiscal year in the series	€ 359,011 Retained profit 2023: € 359,011 ▼ 2% vs 2022 (€ 368,061) Unfavourable step	€ 345,915 Retained profit 2024: € 345,915 ▼ 4% vs 2023 (€ 359,011) Unfavourable step	€ 337,240 Retained profit 2025: € 337,240 ▼ 3% vs 2024 (€ 345,915) Unfavourable step	▼ 3%
Bank debt	€ 77,627 Bank debt 2022: € 77,627 First fiscal year in the series	€ 61,704 Bank debt 2023: € 61,704 ▼ 21% vs 2022 (€ 77,627) Favourable step	€ 45,232 Bank debt 2024: € 45,232 ▼ 27% vs 2023 (€ 61,704) Favourable step	€ 28,191 Bank debt 2025: € 28,191 ▼ 38% vs 2024 (€ 45,232) Favourable step	▼ 38%
Balance sheet total	€ 531,577 Balance sheet total 2022: € 531,577 First fiscal year in the series	€ 553,781 Balance sheet total 2023: € 553,781 ▲ 4% vs 2022 (€ 531,577) Unchanged	€ 819,294 Balance sheet total 2024: € 819,294 ▲ 48% vs 2023 (€ 553,781) Unchanged	€ 787,861 Balance sheet total 2025: € 787,861 ▼ 4% vs 2024 (€ 819,294) Unchanged	▼ 4%

Key figures of DRAGONPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DRAGONPHARMA?

What happened at DRAGONPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 24, 2026 New annual accounts for financial year 2025: loss of € 8,675. Source: NBB ↗
Jul 5, 2012 Start of the company according to the CBE. KBO
Jul 4, 2012 New establishment in Colfontaine. KBO

In short

From € 2,672 loss in 2022 to € 8,675 loss in 2025.

Paid € 2 in corporate taxes since 2022.

Original PDFs at the National Bank ↗

Management

CONEMPHAR 100%

The stake of CONEMPHAR comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

DRAGONPHARMA

Behind DRAGONPHARMA is Pascal Conem. The shares are held by CONEMPHAR (100%).

Directors

According to the 2025 annual accounts

Pascal Conem

Director

Also active at: CONEMPHAR

Shareholders

CONEMPHAR

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Jean Jean 3

7340 Colfontaine

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0847.159.297
VAT number: BE 0847.159.297
Registered office: Rue Jean Jean 3, 7340 Colfontaine
Names & denominations: DRAGONPHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 5 July 2012
Peppol: Active · Active since 16 Dec 2025

View on CBE Public ↗ Annual accounts (NBB) ↗